Summary: Cell free DNA screening for fetal aneuploidy became commercially available in 2011. This podcast will review the science, benefits, and limitations of this screening modality for fetal aneuploidy. Data extrapolated from ACOG Committee Opinion #640, and the SMFM Committee on Genetics.
